Acinar adenocarcinoma

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Acinar adenocarcinoma is a histological subtype of gland-forming cancer that is diagnosed when cuboidal and/or columnar shaped malignant cells in the neoplastic tissue form acini and tubules.[1] It is a common form of cancer occurring in the lung and prostate gland.

Acinar adenocarcinoma of the lung[edit]

Adenocarcinoma ("adeno" = "gland", "carcinoma" = cancer of epithelium) is the most common type of lung cancer in the U.S., Japan, and most of Western Europe, although it is the second most common form in Eastern parts of Europe (after squamous cell carcinoma).[2] Adenocarcinomas are exceptionally heterogeneous neoplasms, occurring in four major tissue architectures (acinar, papillary, bronchioloalveolar, and solid), and several rarer variants. Most commonly, however, these lesions show a mixture of two or more subtypes or variants, and are subclassified as "adenocarcinoma with mixed subtypes".[1][2]

In China, which has the largest number of smokers and lung cancer cases in the world, the acinar tissue architectural pattern is by far the most common histological subtype of adenocarcinoma, comprising about 40% of all adenocarcinomas,[3] and its incidence has increased significantly in recent decades.[4] In Europe, acinar adenocarcinoma may comprise the dominant architectural pattern in as many as 50–60% of all adenocarcinomas.[5]

Acinar adenocarcinoma of the lung is a highly lethal disease. Overall five-year survival rates approximate 16% to 22%. Generally, survival is better in all stages for patients with the acinar (or papillary) pattern than it is in patients with the solid pattern, but considerably worse than those with the bronchioloalveolar pattern.[5][6] Survival is significantly better in patients whose tumors are well differentiated (i.e. the glands and/or tubules are more completely developed) than when poorly differentiated (i.e. with rudimentary glands).[7]

Some studies suggest that the oncogenes H-ras and fes are important drivers of oncogenesis in many acinar-type lung cancers.[8]

Acinar adenocarcinoma of the prostate[edit]

Acinar adenocarcinomas are the most common form of prostate gland malignancy.[9]

References[edit]

  1. ^ a b Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; Harris, Curtis C, eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN 92 832 2418 3. 
  2. ^ a b Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C (June 2006). "Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping". Ann. Thorac. Surg. 81 (6): 1988–95. PMID 16731118. doi:10.1016/j.athoracsur.2006.01.021. 
  3. ^ Huang ZY (July 1988). "[Pathologic analysis of 302 primary bronchogenic adenocarcinomas]". Zhonghua Zhong Liu Za Zhi (in Chinese). 10 (4): 280–3. PMID 3248485. 
  4. ^ Jia X, He A, Zhang D, Wang E, Song J (October 2001). "[Comparison and analysis of clinicopathology of lung cancer between 1980s and 1990s in the Shenyang area (1,224 cases)]". Zhonghua Bing Li Xue Za Zhi (in Chinese). 30 (5): 332–5. PMID 11769727. 
  5. ^ a b Sørensen JB, Hirsch FR, Olsen J (July 1988). "The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease". Cancer. 62 (2): 361–7. PMID 3383137. doi:10.1002/1097-0142(19880715)62:2<361::AID-CNCR2820620222>3.0.CO;2-M. 
  6. ^ Sørensen JB, Olsen JE (February 1989). "Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung". J. Thorac. Cardiovasc. Surg. 97 (2): 245–51. PMID 2915561. 
  7. ^ Chapelier A, Fadel E, Macchiarini P, et al. (November 2000). "Factors affecting long-term survival after en-bloc resection of lung cancer invading the chest wall". Eur J Cardiothorac Surg. 18 (5): 513–8. PMID 11053809. doi:10.1016/S1010-7940(00)00537-6. 
  8. ^ Nishio H, Nakamura S, Horai T, Ikegami H, Matsuda M (March 1992). "Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer". Cancer. 69 (5): 1130–6. PMID 1310887. doi:10.1002/cncr.2820690512. 
  9. ^ Randolph TL, Amin MB, Ro JY, Ayala AG (June 1997). "Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance". Mod. Pathol. 10 (6): 612–29. PMID 9195581. 

External links[edit]